ToxPharm is an independent toxicology and regulatory science consultancy providing defensible, science-driven risk assessments for complex and emerging products. We specialize in translating toxicological data into clear regulatory strategies that support product development, market access, and long-term compliance.

Founded by Bonnie Coffa, PhD, ToxPharm operates at the intersection of toxicology, risk assessment, and regulatory decision-making, supporting clients across highly scrutinized product categories including nicotine and tobacco products, consumer goods, ingredients, and novel technologies.

Our work is grounded in internationally accepted scientific standards and aligned with global regulatory frameworks, including FDA, OECD, ICH, EFSA, and ECHA guidance. We focus on generating and interpreting evidence that can withstand regulatory review—whether for ingredient safety assessments, comparative risk evaluations, or premarket submissions.

Strategic Partners

ToxPharm collaborates with a select group of strategic partners to deliver integrated, high-level scientific and regulatory support for complex and highly scrutinized products. These collaborations enhance our ability to support industry, law firms, and consulting teams while maintaining independence and scientific rigor.

• ToxSynergy 
  Regulatory toxicology and strategic advisory support across complex product categories, strengthening integrated risk assessment and regulatory strategies.

• CST Innovations 
  Experienced engineer with over 100 patents in the nicotine and tobacco space, CST Innovations provides deep expertise in device design, engineering analysis, competitive intelligence, and litigation support for nicotine and tobacco products.

• Vitronix
  Vitronix offers advanced in vitro toxicology and aerosol collection methods, along with expertise in device physical parameter characterization and study approaches supporting the evaluation of inhalation and novel delivery systems.